FibroGen Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 1 sell rating, 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FibroGen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FGEN, but not buy additional shares or sell existing shares.
View analyst ratings for FibroGen or view top-rated stocks.

Wall Street analysts have given FibroGen a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but FibroGen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

FibroGen is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for FibroGen.

FibroGen, Inc. (NASDAQ:FGEN) issued its earnings results on Sunday, February, 28th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $0.35. The biopharmaceutical company had revenue of $65 million for the quarter, compared to the consensus estimate of $100.82 million. FibroGen had a negative net margin of 191.78% and a negative trailing twelve-month return on equity of 48.19%. The company's quarterly revenue was up 712.5% compared to the same quarter last year. During the same period last year, the company posted ($1.12) EPS.
View FibroGen's earnings history.

FibroGen's stock was trading at $35.40 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, FGEN shares have decreased by 40.3% and is now trading at $21.12.
View which stocks have been most impacted by COVID-19.

8 equities research analysts have issued 1 year price objectives for FibroGen's shares. Their forecasts range from $29.00 to $58.00. On average, they anticipate FibroGen's stock price to reach $45.83 in the next year. This suggests a possible upside of 117.0% from the stock's current price.
View analysts' price targets for FibroGen or view top-rated stocks among Wall Street analysts.

Some companies that are related to FibroGen include Arrowhead Pharmaceuticals (ARWR), Ultragenyx Pharmaceutical (RARE), Ascendis Pharma A/S (ASND), GW Pharmaceuticals (GWPH), Evotec (EVTCY), Ionis Pharmaceuticals (IONS), TG Therapeutics (TGTX), Allakos (ALLK), Perrigo (PRGO), Sarepta Therapeutics (SRPT), Blueprint Medicines (BPMC), Galapagos (GLPG), Schrödinger (SDGR), Biohaven Pharmaceutical (BHVN) and Sage Therapeutics (SAGE).
View all of FGEN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

(FGEN) raised $146 million in an IPO on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

FibroGen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Polianta Ltd (0.04%), EFG Asset Management Americas Corp. (0.01%) and Pacer Advisors Inc. (0.00%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, Enrique A Conterno, James A Schoeneck, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Thomas B Neff and Thomas F Kearns Jr.
View institutional ownership trends for FibroGen.

FGEN stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have sold FibroGen company stock in the last year include K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, and Thomas F Kearns Jr.
View insider buying and selling activity for FibroGen or view top insider-selling stocks.

FGEN stock was purchased by a variety of institutional investors in the last quarter, including Polianta Ltd, and EFG Asset Management Americas Corp..
View insider buying and selling activity for FibroGen or or view top insider-buying stocks.

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FGEN stock can currently be purchased for approximately $21.12.

FibroGen has a market capitalization of $1.94 billion and generates $256.58 million in revenue each year. The biopharmaceutical company earns $-76,970,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.

FibroGen employs 599 workers across the globe.

The official website for FibroGen is www.fibrogen.com.

FibroGen is headquartered at 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158.

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]